• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAA
Click for more information
6.98% 23.0¢

PHARMAUST LIMITED - Announcements

Market Cap $82.69M  ! watchlist Created with Sketch. Add to my watchlist

PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for... PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Company’s segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
PAA Appendix 4D & Financial Report - Dec 2016PRICE SENSITIVE28/02/17
PAA Appendix 4C - Quarterly Report & Company UpdatePRICE SENSITIVE31/01/17
PAA PharmAust Receives $406K R&D Rebate from ATOPRICE SENSITIVE30/01/17
PAA Appendix 3B & s708 Notice03/01/17
PAA PharmAust raises a further $1.56m30/12/16
PAA Change of Director's Interest Notice x 413/12/16
PAA Completion of Rights Issue & Notice of Shortfall08/12/16
PAA No Extension of Closing Date in Rights Issue06/12/16
PAA Rights Issue - Extension of Closing Date05/12/16
PAA Phase II Strategy UpdatePRICE SENSITIVE21/11/16
PAA Results of Annual General Meeting11/11/16
PAA PharmAust AGM Presentation11/11/16
PAA Appendix 3B08/11/16
PAA Letter to Optionholders08/11/16
PAA ProspectusPRICE SENSITIVE08/11/16
PAA Appendix 4C - Quarterly Report & Company Update-PAA.AX PRICE SENSITIVE31/10/16
PAA Second canine receives treatment in trial-PAA.AX 14/10/16
PAA Notice of Annual General Meeting/Proxy Form-PAA.AX 11/10/16
PAA Phase II Canine Trial begins at University of Cambridge-PAA.AX PRICE SENSITIVE19/09/16
PAA Epichem achieves ISO 9001 2015 certification-PAA.AX PRICE SENSITIVE16/09/16
PAA MPL capsules shipped to centres in NSW & Qld for Phase II-PAA.AX PRICE SENSITIVE13/09/16
PAA Appendix 4G & Corporate Governance Statement-PAA.AX 31/08/16
PAA Appendix 4E & Full Year Statutory Accounts 2016-PAA.AX PRICE SENSITIVE31/08/16
PAA PharmAust Investor Presentation - August 2016-PAA.AX 29/08/16
PAA Further Canine Trials to be Initiated in Australia-PAA.AX PRICE SENSITIVE10/08/16
PAA IP exchange with UNSW consolidates MPL patent position-PAA.AX PRICE SENSITIVE03/08/16
PAA Appendix 4C Quarterly & Brief Company Update - June 2016-PAA.AX PRICE SENSITIVE29/07/16
PAA Investor Call-PAA.AX 19/07/16
PAA Reformulated MPL capsules completed, Phase II to commence-PAA.AX PRICE SENSITIVE11/07/16
PAA University of Cambridge to begin Phase II Trial-PAA.AX PRICE SENSITIVE27/06/16
PAA Epichem Successful in AusTrade Grant-PAA.AX PRICE SENSITIVE16/06/16
PAA Mandate signed to raise capital in USA & list on NASDAQ-PAA.AX 02/06/16
PAA Appendix 4C Quarterly Report & Brief Company Update-PAA.AX PRICE SENSITIVE29/04/16
PAA RedChip issues research on PharmAust11/03/16
PAA Strategy for Phase II Clinical Trial of MonepantelPRICE SENSITIVE08/03/16
PAA Appendix 4D & Half Yearly Report and AccountsPRICE SENSITIVE29/02/16
PAA PharmAust Featured on The RedChip Money Report on Bloomberg12/02/16
PAA PharmAust to Present at RedChip Global Online Microcap Conf08/02/16
PAA Notice of Allowance received from USA Patent OffIcePRICE SENSITIVE05/02/16
PAA PharmAust Receives $546K R&D Rebate from ATOPRICE SENSITIVE01/02/16
PAA Appendix 4C - Quarterly Report & Company UpdatePRICE SENSITIVE29/01/16
PAA USA Roadshow Presentation - January 201618/01/16
PAA Juniper Pharma Services to reformulate MPL for Phase IIPRICE SENSITIVE11/01/16
PAA PharmAust Featured on RedChip Money Report on Bloomberg04/01/16
PAA Epichem Awarded Two Year Contract Extension from DNDiPRICE SENSITIVE21/12/15
PAA Change of Director's Interest Notice08/12/15
PAA Appendix 3B & 708 Notice04/12/15
PAA Change of Director's Interest Notice03/12/15
PAA Change of Director's Interest Notice02/12/15
PAA GenScript Further Pre-Clinical Validation for Phase II TrialPRICE SENSITIVE26/11/15
PAA RedChip appointed to begin Global Investor Relations Program24/11/15
PAA Change of Director's Interest Notice06/11/15
PAA Change of Director's Interest Notice05/11/15
PAA Appendix 3B05/11/15
PAA Quarterly Report & Company UpdatePRICE SENSITIVE30/10/15
PAA Consolidation of Capital28/10/15
PAA Final Director's Interest Notice28/10/15
PAA Results of Annual General Meeting27/10/15
PAA PharmAust AGM Presentation 201527/10/15
PAA Change of Director's Interest Notice22/10/15
PAA Clinical Trial Report Following Phase I TrialPRICE SENSITIVE21/10/15
PAA Change of Registered Office & Principal Place of Business19/10/15
PAA Epichem's New Laboratory Completed29/09/15
PAA Consolidation/Split - PAAPRICE SENSITIVE22/09/15
PAA PharmAust Annual Report 201522/09/15
PAA Notice of Annual General Meeting/Proxy FormPRICE SENSITIVE22/09/15
PAA Appendix 3B & 708 Notice04/09/15
PAA Appendix 4E & Full Year Statutory AccountsPRICE SENSITIVE28/08/15
PAA Appendix 4G & Corporate Governance Statement28/08/15
PAA Professor Morris plans to retire from PharmAust board24/08/15
PAA Change of Director's Interest Notice12/08/15
PAA Clarification on Expiry of Listed Options03/08/15
PAA Letter to Optionholders03/08/15
PAA Appendix 4C - Quarterly Report & Company UpdatePRICE SENSITIVE28/07/15
PAA Phase I Trial at RAH Meets Safety & Cancer Marker End PointsPRICE SENSITIVE23/07/15
PAA Trading HaltPRICE SENSITIVE22/07/15
PAA First Two Canines Complete Combination Therapy With PPL-1PRICE SENSITIVE16/07/15
PAA PharmAust Receives ATO Research & Development RebatePRICE SENSITIVE24/06/15
PAA PharmAust Initiates Combination Therapy Evaluations in Dogs17/06/15
PAA Change of registry address12/06/15
PAA Change of Share Registry Address12/06/15
PAA Appendix 3B & s708 Notice02/06/15
PAA Results of Meeting26/05/15
PAA EGM Shareholder Presentation26/05/15
PAA Second Dog Shows Suppression of Cancer Marker at Days 3 & 7PRICE SENSITIVE19/05/15
PAA Reduction of further Cancer Marker confirmed in Human TrialPRICE SENSITIVE11/05/15
PAA First Dog Shows Suppression of Cancer MarkerPRICE SENSITIVE01/05/15
PAA Appendix 4C Quarterly Report & Company UpdatePRICE SENSITIVE22/04/15
PAA Notice of General Meeting/Proxy Form21/04/15
PAA Approval of Dose Escalation of PPL-1 in Human TrialPRICE SENSITIVE15/04/15
PAA Modification of Clinical Trial in DogsPRICE SENSITIVE13/04/15
PAA Lyell McEwin Hospital approved to join PharmAust trialPRICE SENSITIVE08/04/15
PAA PharmAust Broker Roadshow Presentation - April 201501/04/15
PAA Joint Patent with Japanese Corporation now publishedPRICE SENSITIVE31/03/15
PAA Final Patient in Cohort Demonstrates Tumour Marker ReductionPRICE SENSITIVE24/03/15
PAA Appendix 3B and s708 Notice20/03/15
PAA PharmAust Shareholder Presentation - March 201519/03/15
PAA Completion of Lowest Dose Cohort in Human Cancer TrialPRICE SENSITIVE17/03/15
PAA PharmAust completes $3.14m Share Placement oversubscribedPRICE SENSITIVE16/03/15
PAA Trading HaltPRICE SENSITIVE12/03/15
PAA Appendix 4D & Financial Report - Dec 2016
28/02/17PRICE SENSITIVE
PAA Appendix 4C - Quarterly Report & Company Update
31/01/17PRICE SENSITIVE
PAA PharmAust Receives $406K R&D Rebate from ATO
30/01/17PRICE SENSITIVE
PAA Appendix 3B & s708 Notice
03/01/17
PAA PharmAust raises a further $1.56m
30/12/16
PAA Change of Director's Interest Notice x 4
13/12/16
PAA Completion of Rights Issue & Notice of Shortfall
08/12/16
PAA No Extension of Closing Date in Rights Issue
06/12/16
PAA Rights Issue - Extension of Closing Date
05/12/16
PAA Phase II Strategy Update
21/11/16PRICE SENSITIVE
PAA Results of Annual General Meeting
11/11/16
PAA PharmAust AGM Presentation
11/11/16
PAA Appendix 3B
08/11/16
PAA Letter to Optionholders
08/11/16
PAA Prospectus
08/11/16PRICE SENSITIVE
PAA Appendix 4C - Quarterly Report & Company Update-PAA.AX
31/10/16PRICE SENSITIVE
PAA Second canine receives treatment in trial-PAA.AX
14/10/16
PAA Notice of Annual General Meeting/Proxy Form-PAA.AX
11/10/16
PAA Phase II Canine Trial begins at University of Cambridge-PAA.AX
19/09/16PRICE SENSITIVE
PAA Epichem achieves ISO 9001 2015 certification-PAA.AX
16/09/16PRICE SENSITIVE
PAA MPL capsules shipped to centres in NSW & Qld for Phase II-PAA.AX
13/09/16PRICE SENSITIVE
PAA Appendix 4G & Corporate Governance Statement-PAA.AX
31/08/16
PAA Appendix 4E & Full Year Statutory Accounts 2016-PAA.AX
31/08/16PRICE SENSITIVE
PAA PharmAust Investor Presentation - August 2016-PAA.AX
29/08/16
PAA Further Canine Trials to be Initiated in Australia-PAA.AX
10/08/16PRICE SENSITIVE
PAA IP exchange with UNSW consolidates MPL patent position-PAA.AX
03/08/16PRICE SENSITIVE
PAA Appendix 4C Quarterly & Brief Company Update - June 2016-PAA.AX
29/07/16PRICE SENSITIVE
PAA Investor Call-PAA.AX
19/07/16
PAA Reformulated MPL capsules completed, Phase II to commence-PAA.AX
11/07/16PRICE SENSITIVE
PAA University of Cambridge to begin Phase II Trial-PAA.AX
27/06/16PRICE SENSITIVE
PAA Epichem Successful in AusTrade Grant-PAA.AX
16/06/16PRICE SENSITIVE
PAA Mandate signed to raise capital in USA & list on NASDAQ-PAA.AX
02/06/16
PAA Appendix 4C Quarterly Report & Brief Company Update-PAA.AX
29/04/16PRICE SENSITIVE
PAA RedChip issues research on PharmAust
11/03/16
PAA Strategy for Phase II Clinical Trial of Monepantel
08/03/16PRICE SENSITIVE
PAA Appendix 4D & Half Yearly Report and Accounts
29/02/16PRICE SENSITIVE
PAA PharmAust Featured on The RedChip Money Report on Bloomberg
12/02/16
PAA PharmAust to Present at RedChip Global Online Microcap Conf
08/02/16
PAA Notice of Allowance received from USA Patent OffIce
05/02/16PRICE SENSITIVE
PAA PharmAust Receives $546K R&D Rebate from ATO
01/02/16PRICE SENSITIVE
PAA Appendix 4C - Quarterly Report & Company Update
29/01/16PRICE SENSITIVE
PAA USA Roadshow Presentation - January 2016
18/01/16
PAA Juniper Pharma Services to reformulate MPL for Phase II
11/01/16PRICE SENSITIVE
PAA PharmAust Featured on RedChip Money Report on Bloomberg
04/01/16
PAA Epichem Awarded Two Year Contract Extension from DNDi
21/12/15PRICE SENSITIVE
PAA Change of Director's Interest Notice
08/12/15
PAA Appendix 3B & 708 Notice
04/12/15
PAA Change of Director's Interest Notice
03/12/15
PAA Change of Director's Interest Notice
02/12/15
PAA GenScript Further Pre-Clinical Validation for Phase II Trial
26/11/15PRICE SENSITIVE
PAA RedChip appointed to begin Global Investor Relations Program
24/11/15
PAA Change of Director's Interest Notice
06/11/15
PAA Change of Director's Interest Notice
05/11/15
PAA Appendix 3B
05/11/15
PAA Quarterly Report & Company Update
30/10/15PRICE SENSITIVE
PAA Consolidation of Capital
28/10/15
PAA Final Director's Interest Notice
28/10/15
PAA Results of Annual General Meeting
27/10/15
PAA PharmAust AGM Presentation 2015
27/10/15
PAA Change of Director's Interest Notice
22/10/15
PAA Clinical Trial Report Following Phase I Trial
21/10/15PRICE SENSITIVE
PAA Change of Registered Office & Principal Place of Business
19/10/15
PAA Epichem's New Laboratory Completed
29/09/15
PAA Consolidation/Split - PAA
22/09/15PRICE SENSITIVE
PAA PharmAust Annual Report 2015
22/09/15
PAA Notice of Annual General Meeting/Proxy Form
22/09/15PRICE SENSITIVE
PAA Appendix 3B & 708 Notice
04/09/15
PAA Appendix 4E & Full Year Statutory Accounts
28/08/15PRICE SENSITIVE
PAA Appendix 4G & Corporate Governance Statement
28/08/15
PAA Professor Morris plans to retire from PharmAust board
24/08/15
PAA Change of Director's Interest Notice
12/08/15
PAA Clarification on Expiry of Listed Options
03/08/15
PAA Letter to Optionholders
03/08/15
PAA Appendix 4C - Quarterly Report & Company Update
28/07/15PRICE SENSITIVE
PAA Phase I Trial at RAH Meets Safety & Cancer Marker End Points
23/07/15PRICE SENSITIVE
PAA Trading Halt
22/07/15PRICE SENSITIVE
PAA First Two Canines Complete Combination Therapy With PPL-1
16/07/15PRICE SENSITIVE
PAA PharmAust Receives ATO Research & Development Rebate
24/06/15PRICE SENSITIVE
PAA PharmAust Initiates Combination Therapy Evaluations in Dogs
17/06/15
PAA Change of registry address
12/06/15
PAA Change of Share Registry Address
12/06/15
PAA Appendix 3B & s708 Notice
02/06/15
PAA Results of Meeting
26/05/15
PAA EGM Shareholder Presentation
26/05/15
PAA Second Dog Shows Suppression of Cancer Marker at Days 3 & 7
19/05/15PRICE SENSITIVE
PAA Reduction of further Cancer Marker confirmed in Human Trial
11/05/15PRICE SENSITIVE
PAA First Dog Shows Suppression of Cancer Marker
01/05/15PRICE SENSITIVE
PAA Appendix 4C Quarterly Report & Company Update
22/04/15PRICE SENSITIVE
PAA Notice of General Meeting/Proxy Form
21/04/15
PAA Approval of Dose Escalation of PPL-1 in Human Trial
15/04/15PRICE SENSITIVE
PAA Modification of Clinical Trial in Dogs
13/04/15PRICE SENSITIVE
PAA Lyell McEwin Hospital approved to join PharmAust trial
08/04/15PRICE SENSITIVE
PAA PharmAust Broker Roadshow Presentation - April 2015
01/04/15
PAA Joint Patent with Japanese Corporation now published
31/03/15PRICE SENSITIVE
PAA Final Patient in Cohort Demonstrates Tumour Marker Reduction
24/03/15PRICE SENSITIVE
PAA Appendix 3B and s708 Notice
20/03/15
PAA PharmAust Shareholder Presentation - March 2015
19/03/15
PAA Completion of Lowest Dose Cohort in Human Cancer Trial
17/03/15PRICE SENSITIVE
PAA PharmAust completes $3.14m Share Placement oversubscribed
16/03/15PRICE SENSITIVE
PAA Trading Halt
12/03/15PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
23.0¢ 		Change
0.015(6.98%) 		Mkt cap ! $82.69M
Open High Low Value Volume
21.5¢ 23.0¢ 21.5¢ $475.3K 2.128M

Buyers (Bids)

No. Vol. Price($)
4 93524 22.5¢
 

Sellers (Offers)

Price($) Vol. No.
23.0¢ 71004 2
View Market Depth
Last trade - 16.10pm 14/10/2024 (20 minute delay) ?
PAA (ASX) Chart

Top Stories

Quit before you're fired: Russia bans uranium exports to USA, duplicating extant US ban

Russia's ban of uranium exports to the USA came days before Biden allowed Ukraine use long-range missiles.
Power gets set for 1000-metre maiden drilling program in Brazil Power Minerals Ltd is planning a maiden drilling program to 1000 metres to test targets at its Nióbio project in Brazil
US election outcomes: Key economic and market takeaways This week on Money @ Investing, Mitch Olarenshaw and I break down the recent U.S. presidential election, focusing on its effects on the stock market and the broader economic outlook. Here’s what we covered:1. Election results and policy insightsThe Republican Party&CloseCurlyQuote...
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.